Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha-Linolenic Acid for Cognitive Decline in APOE4 Older Adults With MCI
NCT07392723Phase 2Recruiting
- Start
- Jan 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing ALA Group with Placebo Control Group (2 arms). Primary endpoints: Change in global cognitive function at 6 months, Change in Blood-Brain Barrier Integrity at 6 months and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
Alpha-linolenic acid
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07392723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392723.